Lantheus Exit: $28 Million Sale Comes as Earnings Fall 77% Year Over Year

New York City-based Nitorum Capital fully exited its stake in Lantheus Holdings ( LNTH 2.18%), selling 344,444 shares with an estimated transaction value of $28.2 million, according to a November 14 SEC filing. What Happened Nitorum Capital disclosed in a November 14 SEC filing that it sold its entire holding in Lantheus Holdings ( LNTH 2.18%) during the third quarter. The firm eliminated approximately 344,000 shares, resulting in a net position change of approximately $28.20 million. The fund’s 13F reportable assets under management now total $569.28 million across 27 positions following the transaction. What Else to Know Lantheus Holdings previously represented 4.2% of AUM as of June 30. Top holdings after the filing: NYSE:MLM: $50.13 million (8.8% of AUM) NASDAQ:CHDN: $45.38 million (8.0% of AUM) NASDAQ:MNKD: $35.24 million (6.2% of AUM) NYSE:DELL: $33.38 million (5.9% of AUM) NYSE:RBA: $31.74 million (5.6% of AUM) As of Tuesday, Lantheus Holdings shares were priced at $66.53, down 27% over the past year and well underperforming the S&P 500, which is up 15% in the same period. Company Overview Metric Value Revenue (TTM) $1.53 billion Net Income (TTM) $167.68 million Price (as of Tuesday) $66.53 One-Year Price Change (27%) Company Snapshot Lantheus Holdings offers diagnostic and therapeutic products including DEFINITY (ultrasound agent), TechneLite (technetium generator), PYLARIFY (PSMA imaging), and AZEDRA (radiotherapeutic), as well as AI-enabled imaging software for oncology and cardiology applications. The company generates revenue primarily through the sale and licensing of proprietary imaging agents, radiopharmaceuticals, and related medical devices used in the diagnosis and treatment of cardiovascular disease, cancer, and other serious conditions. It serves radiopharmacies, hospitals, clinics, integrated delivery networks, and group medical practices globally, targeting healthcare providers involved in advanced diagnostic imaging and cancer care. Lantheus Holdings, Inc. is a leading developer and manufacturer of imaging diagnostics and targeted therapeutics for oncology and cardiology, leveraging a diversified portfolio of proprietary agents and AI-driven software. The company maintains a strong presence in the radiopharmaceuticals market, supported by strategic partnerships with major healthcare and pharmaceutical organizations. Its focus on innovation and specialized products positions Lantheus as a key supplier to institutions seeking advanced diagnostic and treatment solutions. Foolish Take Nitorum’s move comes at an interesting time for Lantheus. The company still generates serious cash, reporting $384 million in third-quarter revenue and nearly $95 million in free cash flow, but the quality of those earnings is under pressure. GAAP EPS fell to $0.41 from $1.79 a year earlier, while adjusted EPS declined to $1.27, reflecting rising costs tied to acquisitions, integration, and a heavier R&D load. That matters because Lantheus is no longer a simple growth story anchored solely to iPYLARIFY. Sales of its flagship prostate cancer imaging agent declined 7.4% year over year, even as precision diagnostics revenue elsewhere grew. At the same time, management is navigating a CEO retirement, a portfolio reshuffle, and ambitious regulatory timelines with multiple PDUFA dates stretching into 2026. The exit also stands out in context. This portfolio remains diversified across industrials, gaming, and tech, suggesting the...

Preview: ~500 words